Share this video  

BTOG 2023 | Unmet needs in glioblastoma treatment

Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, describes the challenges of treating glioblastoma. Presently, effective therapies may enable patients to live 3 to 5 years longer, though this result is only useful in younger patients or those with O6-methylguanine-DNA-methyltransferase (MGMT)-methylated tumors. In the elderly and in MGMT-unmethylated cases, present therapies do not improve OS beyond 1 year. More research is needed in this area particularly. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research funding from AstraZeneca

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter